Claris Biotherapeutics has announced a significant step forward in its mission to treat sight-threatening conditions by securing $118 million in a Series B financing round. This funding coincides with key executive appointments and positive clinical data for its lead candidate, CSB-001. The company is now well-positioned to advance its therapy for limbal stem cell deficiency (LSCD), a blinding disease with no currently approved drug treatments.
Significant Financial Backing for Pivotal Trials
The $118 million financing was co-led by new investors Samsara Biocapital and Catalio Capital Management, with participation from several other new and existing backers. These proceeds will be instrumental in advancing Claris through its next critical phase of development. The funds are earmarked to complete ongoing clinical trials and support a planned pivotal program for CSB-001, which is scheduled to commence in the first half of 2027.
Strengthening the Leadership Team
To steer its next growth phase, Claris has appointed a team of seasoned industry veterans to its executive suite and board. Stephen Brady, with nearly three decades of experience in corporate strategy and finance, has been named President and Chief Executive Officer. His track record includes key roles in successful company acquisitions and IPOs, such as the sale of Proteolix to Onyx Pharmaceuticals and Immune Design to Merck.
Joining him is Brian Baum as Chief Commercial Officer, who brings over 20 years of commercial strategy and specialty product launch experience. Mr. Baum previously led critical initiatives for the successful U.S. launch of Oxervate® at Dompé Pharmaceuticals. Additionally, recognized biotech entrepreneur Marc de Garidel has been appointed Chairman of the Board, bringing a distinguished history of scaling innovative healthcare companies like Abivax and CinCor Pharma.
A Novel Approach to a Blinding Disease
Limbal stem cell deficiency is a severe eye disease where the stem cells responsible for repairing the corneal surface are destroyed, often leading to vision loss. Claris's lead candidate, CSB-001, is a non-surgical eye drop designed to address the underlying cause of the disease. It works by promoting corneal epithelial regeneration while also modulating inflammation and fibrosis, offering hope as the potential first pharmacologic treatment for LSCD.
Clinical Development and Future Outlook
The company is actively advancing its clinical program based on positive proof-of-concept data showing substantial improvements in visual acuity. An open-label study is currently ongoing, alongside a non-interventional study to understand the natural history of LSCD. These efforts will inform two pivotal studies planned for 2027, which will enroll approximately 400 subjects to evaluate the efficacy and safety of CSB-001.
Executive Vision and Confidence
The new leadership team expressed strong optimism about the company's trajectory and the potential of its lead therapy. Stephen Brady, the new President and CEO, stated he was thrilled to join at such a pivotal moment, highlighting the strong investor interest in CSB-001. He emphasized that with financing secured through Phase 3, the company is poised to advance its promising eye drop treatment from a position of strength.
Marc de Garidel, the new Chairman, echoed this sentiment, noting that Claris is entering a defining period of growth. He thanked the founding CEO for building a strong scientific foundation, which allows the new team to approach this watershed moment with confidence. The leadership is focused on advancing CSB-001 for patients and guiding the company toward commercialization.
With a substantial $118 million in new funding, a fortified leadership team, and a promising therapeutic candidate, Claris Biotherapeutics is strategically positioned for its next chapter. The company's focus on advancing CSB-001 through pivotal trials offers a new beacon of hope for patients suffering from the debilitating effects of LSCD. The upcoming clinical milestones will be closely watched as Claris moves closer to potentially delivering a first-in-class, non-surgical treatment for this blinding condition.